ARG1 and leukemia: Targeting efferocytic macrophages within the spleen and marrow leukemia microenvironments, we demonstrated that MRX2843 decreased macrophage immunosuppressive features including a reduction in M2-like markers PD-L1, PD-L2, Tim-3, CD163, and Arginase-1.